Oncimmune Holdings PLC Satisfaction of Delayed Completion Placing (4074X)
November 24 2017 - 1:00AM
UK Regulatory
TIDMONC
RNS Number : 4074X
Oncimmune Holdings PLC
24 November 2017
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014. Upon the publication of
this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Oncimmune Holdings plc ("Oncimmune" or the "Company")
Satisfaction of the condition under the Delayed Completion
Placing
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R)platform technology announces that it has received
confirmation from HMRC that the Ordinary Share are regarded as a
qualifying holding for the purposes of Part 6 of the Income Tax Act
2007 (the "VCT Condition").
Consequently, the 833,333 Ordinary Shares that were
conditionally placed as part of the placing of 4,166,667 Ordinary
Shares announced on 27 September 2017 ("Delayed Completion Placing
Shares") will now be issued at the placing price of GBP1.20.
Under the terms of the placing, admission of the Delayed
Completion Placing Shares is to occur within 5 business days of
satisfaction of the VCT Condition. Admission is therefore expected
at 8.00 am on 28 November 2017.
Following Admission of the Delayed Completion Placing Shares,
the Company's enlarged issued share capital will comprise
55,216,071 Ordinary Shares of 1 pence each with voting rights in
the Company. This figure may be used by shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in the interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKNDNOBDDNDB
(END) Dow Jones Newswires
November 24, 2017 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024